SURG SurgePays, Inc. Insider Trading

Director David Allen May purchased 40,250 shares across 3 transactions at $0.53 (totaling $21,151.38), raising holdings 34.6% despite stock down 86.4% from 52-week high.

David Allen May, a Director at SurgePays, executed 3 separate purchases totaling 40,250 shares for $21,151.38 between June 3–5, 2026, at a blended price of $0.53 per share. This acquisition increased his holdings from 116,376 to 156,626 shares (+34.6%). The purchases occurred while the stock trades at $0.47, approximately 86.4% below its 52-week high of $3.45 and down 40.1% over 90 days. May's prior purchases at this ticker (December 2025) both yielded negative 90-day returns (−47.0% and −47.7%), establishing a pattern of poor timing at SURG over the measurable window. The company is unprofitable (net income −$12.1M on revenue $16.0M in the latest quarter) and revenue contracted 6.4% year-over-year, creating fundamental headwinds that complicate interpretation of a discounted-price accumulation.

Director David Allen purchased 38,422 shares at $1.60–$1.62 as stock trades 57.1% below 52-week high amid -55.6% revenue decline.

Director David Allen executed 2 separate purchases totaling 38,422 shares for $61,646.78 at a blended average price of $1.60 on December 10, 2025, raising his holdings 32.1% to 158,116 shares. The purchase occurs as the stock trades at $1.47, down 57.1% from its 52-week high of $3.43 and down 48.4% over the prior 30 days, while the company reports negative net income of -$7,489,068.00 in the latest quarter and annual revenue contraction of -55.6%. This discretionary acquisition by a director of a materially distressed company—operating unprofitably with collapsing revenue growth—at depressed valuations represents a notable accumulation against a backdrop of severe operational deterioration.

SURG CEO Cox buys 15,073 shares at $2.75; reiterates buy discipline amid -55.6% revenue decline and $-7.6M net loss.

Cox Kevin Brian, CEO and Chairman, purchased 15,073 shares at $2.75 on 2025-05-16, expanding his holdings to 5,785,163 shares. This represents a modest 0.3% addition to his stake, executed at a price 5.5% below the current $2.91 level. The transaction mirrors his prior SURG buy from 2023-08-15, which delivered a 90d return of +18.2%, demonstrating consistent timing discipline at this ticker. However, the buy occurs within a deteriorating operational backdrop: FY revenue contracted -55.6% year-over-year to $10,577,429.00 (latest quarter), and the company posted a full-year net loss of $-7,635,084.00. The insider's cross-ticker track record shows 1 prior buy with a 90d average return of +18.2% and 100% win rate, but the small position increment and unprofitable state make this acquisition a narrow data point requiring deeper operational context to assess conviction or capital allocation priority.

Director Weisberg Laurie purchased 7,808 shares (7.8K shares) for $13,971.59 ($14.0K) across 6 transactions at blended average $1.79

Laurie Weisberg, a director at SurgePays, Inc., made 6 separate purchases totaling 7,808 shares for $13,971.59 between November 22–25, 2024, at prices ranging from $1.67 to $1.84 and a blended average of $1.79. This transaction brings her holdings from 0 to 7,809 shares post-transaction, representing a new position established over a concentrated window. At the current price of $2.01, the position is in modest gains; however, the stock is -77.6% from its 52-week high of $8.97, reflecting significant deterioration from recent peaks. SurgePays reported a net loss of $-14.3M against quarterly revenue of $4.8M, indicating material operational challenges that may warrant close monitoring of whether further insider acquisitions signal confidence in a turnaround or reflect accumulation at depressed valuations.

Director Schurfeld buys 3,500 shares at $1.59–$1.64 as SURG stock trades -83.7% from 52-week high

Richard Earl Schurfeld, a director, executed 2 separate purchases totaling 3,500 shares for $5,593.42 on 2024-11-15, increasing his holdings from 44,001 to 47,501 shares (+8.0%). The buys occurred at a blended average price of $1.60, but the current stock price is $1.46, already down -22.3% over the past 30 days and trading -83.7% from its 52-week high of $8.97. Schurfeld's prior buy at this ticker on 2024-09-13 generated a +36.7% 30-day return, though the company's fundamentals present headwinds: the latest quarter showed revenue of $4,769,697.00 against a net loss of $-14,275,347.00. The insider's cross-ticker track record shows 1 prior buy with avg 30d return +36.7%, suggesting some historical success in timing entry points, but absence of measurable 90-day outcomes on recent same-ticker trades leaves conviction timing on this filing unvalidated at the longer horizon.